
Unveiling novel 2-cyclopropyl-3-ethynyl-4-(4-fluorophenyl)quinolines as GPCR ligands via PI3-kinase/PAR-1 antagonism and platelet aggregation valuations; development of a new class of anticancer drugs with thrombolytic effects
Keywords: Anti-inflammatory; Anticancer; GPCR ligands; Molecular docking; MTT assay; PAR1; PI3Kinase; Quinolines; XRD;